Hetrombopag for Pediatric Patients With Chronic Immune Thrombocytopenia
Status:
Not yet recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the efficacy, safety of Hetrombopag in children
with previously treated chronic immune thrombocytopenia who are between 6 and 17 years of
age. This is a 2 part study. In part A, patients will receive Hetrombopag for 8 weeks. In
part B, all patients will receive Hetrombopag for 24 weeks.